Insider Selling: Intellia Therapeutics (NASDAQ:NTLA) EVP Sells $84,186.00 in Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Edward Dulac III sold 4,677 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the sale, the executive vice president directly owned 156,286 shares of the company’s stock, valued at $2,813,148. The trade was a 2.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Intellia Therapeutics Stock Performance

NTLA traded up $0.28 on Monday, hitting $17.84. The company had a trading volume of 3,834,214 shares, compared to its average volume of 5,666,633. The stock has a market capitalization of $2.49 billion, a price-to-earnings ratio of -5.04 and a beta of 1.77. Intellia Therapeutics, Inc. has a 12-month low of $7.95 and a 12-month high of $28.25. The stock has a fifty day moving average price of $14.13 and a 200-day moving average price of $13.07.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. The business had revenue of $15.05 million for the quarter, compared to the consensus estimate of $13.81 million. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.During the same period in the prior year, the firm posted ($1.10) earnings per share. Analysts forecast that Intellia Therapeutics, Inc. will post -3.18 EPS for the current fiscal year.

Institutional Investors Weigh In On Intellia Therapeutics

Large investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC increased its stake in Intellia Therapeutics by 19.2% in the fourth quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock valued at $127,724,000 after purchasing an additional 2,288,146 shares during the last quarter. Vanguard Group Inc. raised its stake in Intellia Therapeutics by 17.8% during the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after acquiring an additional 1,965,181 shares during the last quarter. State Street Corp lifted its holdings in shares of Intellia Therapeutics by 29.1% during the fourth quarter. State Street Corp now owns 6,418,836 shares of the company’s stock worth $57,705,000 after purchasing an additional 1,447,967 shares during the period. Baker BROS. Advisors LP raised its holdings in Intellia Therapeutics by 2.7% during the third quarter. Baker BROS. Advisors LP now owns 2,746,674 shares of the company’s stock worth $47,435,000 after purchasing an additional 71,000 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Intellia Therapeutics by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 2,696,187 shares of the company’s stock valued at $24,243,000 after buying an additional 107,333 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Morgan Stanley lifted their price objective on shares of Intellia Therapeutics from $11.00 to $15.00 and gave the company an “equal weight” rating in a research note on Monday, April 27th. Citigroup reiterated a “market outperform” rating on shares of Intellia Therapeutics in a research report on Monday, June 15th. Wedbush restated a “neutral” rating and set a $12.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 15th. Leerink Partners set a $35.00 price objective on Intellia Therapeutics in a research note on Monday, April 27th. Finally, Robert W. Baird upped their price target on Intellia Therapeutics from $7.00 to $13.00 and gave the company a “neutral” rating in a research report on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $20.46.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.